Doug Van Cuyk
Contributor since: 2014
Latest Articles
Why Exact Sciences Corporation's Q2 Worries Me
4 Stocks To Help Pay For College Tuition
VolitionRx, Ltd.: Liquid Biopsy Cancer Screening Play
Garmin: An Appealing 5.2% Dividend Yield, A Concerning Revenue/Earnings Trajectory
Illumina, Inc. Is On Sale, Consistent Growth And Market Opportunities Not Appreciated
Covered Call Strategy To Mimic A Dividend Boost In 2016 For General Electric
2 Appealing Covered Calls For Sequenom Offer Nice Short Term Gains
Liquid Biopsy's First Victim, Exact Sciences' Cologuard
At Current Prices, Someone Is Going To Buy Sequenom
Portfolio Reallocation: Sell CLR And Purchase XOM
General Electric: Fool Me Once, Shame On You; Fool Me Twice, Shame On Me
Exact Sciences Had Wildly Successful 2014, Can We Expect The Same In 2015?
Looking Back At 2014 And What To Expect In 2015 For Sequenom
EOG Resources Fits My Criteria As A Potential Future Dividend Aristocrat
BlackRock: Another Future Dividend Aristocrat
Gilead Sciences, Future Dividend Aristocrat In The Making
General Electric: Dividend Aristocrat In The Making
Pacific Biosciences Is Being Eaten Alive By Illumina
If You Like Johnson & Johnson And Abbott Labs, Then You Should Consider Atrion Corporation
Endocyte: Small Company, Small Valuation, Full Pipeline
Continued Expansion Into The Cystic Fibrosis Treatment Market Bodes Well For Vertex
Sequenom's VisibiliT Has A Huge Opportunity In Replacing The First Trimester Screen
The Liquid Biopsy Will Boost Revenue For Sequenom And Illumina
Illumina, An Explosive Opportunity, Currently Slightly Overpriced
Proven Reserves And Production Rates Show Continental Resources Is Undervalued
Suggesting An Entry Point For Atrion
GE Part VIII: Capital Segment Analysis
GE Part VII: Lighting Segment Analysis
GE Part VI: Transportation Segment Analysis
GE Part V: Healthcare Segment Analysis
Listen Up Insurance Companies, Cologuard Will Save You Money
GE Part IV: Aviation Segment Analysis